210 related articles for article (PubMed ID: 30811153)
1. The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes.
Del Rosso JQ; Kircik LH; Zeichner J; Stein Gold L
J Drugs Dermatol; 2019 Feb; 18(2s):s100-s107. PubMed ID: 30811153
[TBL] [Abstract][Full Text] [Related]
2. Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance.
Jackson JM; Pelle M
J Drugs Dermatol; 2011 Jun; 10(6):627-33. PubMed ID: 21637903
[TBL] [Abstract][Full Text] [Related]
3. Importance of vehicles in acne therapy.
Kircik LH
J Drugs Dermatol; 2011 Jun; 10(6):s17-23. PubMed ID: 21780342
[TBL] [Abstract][Full Text] [Related]
4. Principles and approaches for optimizing therapy with unique topical vehicles.
Rosen J; Landriscina A; Friedman AJ
J Drugs Dermatol; 2014 Dec; 13(12):1431-5. PubMed ID: 25607783
[No Abstract] [Full Text] [Related]
5. Formulation design for topical drug and nanoparticle treatment of skin disease.
Raphael AP; Garrastazu G; Sonvico F; Prow TW
Ther Deliv; 2015 Feb; 6(2):197-216. PubMed ID: 25690087
[TBL] [Abstract][Full Text] [Related]
6. A novel foam vehicle for delivery of topical corticosteroids.
Huang X; Tanojo H; Lenn J; Deng CH; Krochmal L
J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S26-38. PubMed ID: 15968261
[TBL] [Abstract][Full Text] [Related]
7. Formulation development of tazarotene-loaded PLGA nanoparticles for follicular delivery in the treatment of inflammatory skin diseases.
Kshirsagar SM; Shrestha N; Kipping T; Banga AK
Eur J Pharm Biopharm; 2024 Jul; 200():114346. PubMed ID: 38823541
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
10. Vehicles Always Matter.
Kircik LH
J Drugs Dermatol; 2019 Feb; 18(2s):s99. PubMed ID: 30811152
[TBL] [Abstract][Full Text] [Related]
11. Conventional topical delivery systems.
Weiss SC
Dermatol Ther; 2011; 24(5):471-6. PubMed ID: 22353153
[TBL] [Abstract][Full Text] [Related]
12. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference.
Housman TS; Mellen BG; Rapp SR; Fleischer AB; Feldman SR
Cutis; 2002 Dec; 70(6):327-32. PubMed ID: 12502121
[TBL] [Abstract][Full Text] [Related]
13. Back to the future: a new topical approach for mild-to-moderate psoriasis.
Girolomoni G; Calzavara Pinton P; Cristaudo A; Cicchetti A
G Ital Dermatol Venereol; 2018 Jun; 153(3):375-382. PubMed ID: 27982547
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Feldman SR; Werner CP; Alió Saenz AB
J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
[TBL] [Abstract][Full Text] [Related]
15. Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?
Giovene GL; Giacomelli L;
G Ital Dermatol Venereol; 2018 Dec; 153(6):872-876. PubMed ID: 30261718
[TBL] [Abstract][Full Text] [Related]
16. The mystical effects of dermatological vehicles.
Surber C; Smith EW
Dermatology; 2005; 210(2):157-68. PubMed ID: 15724099
[TBL] [Abstract][Full Text] [Related]
17. Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability.
Del Rosso JQ; Jitpraphai W; Bhambri S; Momin S
Cutis; 2008 May; 81(5):405-8. PubMed ID: 18543590
[TBL] [Abstract][Full Text] [Related]
18. A Review of Topical Corticosteroid Foams.
Payne J; Habet KA; Pona A; Feldman SR
J Drugs Dermatol; 2019 Aug; 18(8):756-770. PubMed ID: 31424707
[TBL] [Abstract][Full Text] [Related]
19. Influences of the vehicle in the spreading and release of betamethasone.
Molesini S; Urto F; Cvetkovska AD; Bettoli V; Valacchi G; Pecorelli A; Manfredini S; Vertuani S
Ther Deliv; 2018 Feb; 9(3):177-184. PubMed ID: 29424289
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
Feldman SR; Mills M; Brundage T; Eastman WJ
J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
